APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/08/2026
Voltar para busca
Dado oficial do USPTO
BIOSE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
10/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 41, 42
Data de depósito
03/07/2015
Data de registro
11/10/2016
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/01/2023
Última transação
10/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
Arpajon Sur Cere, FR
Examinador
NEVILLE, BRIAN
Unidade examinadora
M50
Titulares e representantes
Titulares
BIOSE INDUSTRIE
BIOSE
Representantes
William S. Fultz Womble Bond Dickinson (US) LLP
Classificação técnica
Classes Nice
Classe 5Classe 41Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical products made with the microbiotabacteriaprobiotics and tribiotics for treating gynecological disordersintestinal disordersgastroenterological disorders linked to imbalances in the intestinal floravaginal floradermatological diseasesimmuneauto-immune and inflammatorydiseases of the earnose and throatallergies; chemical or biological pharmaceutical preparations for pharmaceuticalmedical and sanitary purposesmicrobiotabacteriaprobiotics and tribiotics for treating gynecological disordersintestinal disordersgastroenterological disorders linked to imbalances in the intestinal floravaginal floradermatological diseasesimmuneauto-immune and inflammatorydiseases of the earnose and throatallergies; sanitary and medical preparationsbacteria for use in the composition of biological pharmaceuticals for treating gynecological disordersintestinal disordersgastroenterological disorders linked to imbalances in the intestinal floravaginal floradermatological diseasesimmuneauto-immune and inflammatorydiseases of the earnose and throatallergies; biological or chemical preparations for pharmaceuticalmedical usetoiletprobioticstribiotics in capsulescapsules and sachets for treating or preventing the gastroenterological diseasegyncologicalearnose and throatdermatologicalallergicimmune or inflammatorydiseases associated with an imbalance in the vaginal or intestinal floraflatulencediarrheaabdominal painspasmsfor improving regulation of intestinal transit; vaginal capsules for treating gynecological diseases; preparations for medical useantifungalsantimycoticsantiflatulent agentsantidiarrheic agentsantispasmodicsantiinflammatories or antibiotics; disinfectants for hygiene care of patients suffering from gastroenterological diseasesimbalance of the intestinal floragynecological diseasesimbalance of the vaginal flora; nutritional supplementsfood beveragesbars and meal replacement substances adapted for medical usedietetic purposestreating or preventing gynecological disordersgastroenterologicalintestinal disorders linked to imbalances in the intestinal floravaginal floradermatological diseasesimmuneauto-immune and inflammatorydiseases of the earnose and throat; nutritional supplementsmeal replacement foodsbeveragesbars made from a combination of probioticsminerals and/or vitamins; vitamin preparationsvitamin supplements; medical preparations for slimming; mineral food supplements
Classe 41
Arranging and conducting of educational colloquiumsconferencesseminars and events for scientific purposes in the field of microbiotaof probiotics as pharmaceutical preparationsof the probiotics industryof good practice in the field of microbiotaof probioticsof changes to regulations relating to probiotics and microbiota
Classe 42
Laboratory services for the provision of scientific analysis and research servicesmedicalpharmaceuticalpharmacologicalbacteriologicalchemical and microbiologicaldesign and production of pharmaceutical preparationsprobioticstribiotics for others; consulting in production of pharmaceutical preparations; quality control; testing in laboratory; services for assessing the efficiency of pharmaceuticals; auditing and auditing pharmaceutical manufacturing processes; packaging design services; kitchen design of preventive quality assurance and quality control relating to the manufacture of pharmaceutical preparations; auditing and testing standards and practices in the field of the manufacture of probioticstribioticsensure compliance with governmental regulations and industrial practicespractices quality control and quality assurance; conducting pharmaceutical research projects and technical project studies; engineering; provision of information and data relating to medical and scientific research in the field of pharmaceuticalsprobioticsclinical trials relating to scientific research and development; provision and exchange of knowledgeindustrial know-how and data relating to scientific research and development; provision and exchange of information and data exchange between scientistsmanufacturers and health authorities relating to pharmaceutical regulatory affairs and the application thereof to probiotics; expertise services and technical advice in the field of scientific research for medical and pharmaceutical purposesin the field of probiotics; development and maintenance of data banks and databases; extraction and retrieval of information and data mining; managing of working groups bringing together scientists and manufacturers to resolve problems in connection with probiotics; research and drafting of information provided by scientific research in the field of medical researchpharmaceuticalpharmacological in regulatory affairs in the field of probiotics
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
ES71
TEAS SECTION 71 RECEIVED
05/05/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
22/01/2026
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
11/10/2025
RNWL
INTERNATIONAL REGISTRATION RENEWED
24/07/2025
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
31/10/2023
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
23/09/2023
INPC
INVALIDATION PROCESSED
23/09/2023
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
13/09/2023
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
13/01/2023
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
13/01/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/01/2023
ES71
TEAS SECTION 71 RECEIVED
01/07/2022
CHLD
CHANGE OF OWNER RECEIVED FROM IB
11/09/2020
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
13/03/2017
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/03/2017
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
17/02/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
13/02/2017
FIMP
FINAL DISPOSITION PROCESSED
13/02/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/01/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
11/10/2016
PUBO
PUBLISHED FOR OPPOSITION
26/07/2016
NPUB
NOTICE OF PUBLICATION
06/07/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
20/06/2016
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
16/06/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/06/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/06/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/06/2016
ALIE
ASSIGNED TO LIE
27/05/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/05/2016
RFNT
REFUSAL PROCESSED BY IB
26/03/2016
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/03/2016
RFRR
REFUSAL PROCESSED BY MPU
04/03/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/03/2016
CNRT
NON-FINAL ACTION WRITTEN
03/03/2016
MAFR
APPLICATION FILING RECEIPT MAILED
01/03/2016
DOCK
ASSIGNED TO EXAMINER
25/02/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/02/2016
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
24/02/2016
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
23/02/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BIOSE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.